AVTR saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 61 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 68%.
The Moving Average Convergence Divergence (MACD) for AVTR just turned positive on October 15, 2026. Looking at past instances where AVTR's MACD turned positive, the stock continued to rise in 30 of 45 cases over the following month. The odds of a continued upward trend are 67%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVTR advanced for three days, in 172 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 110 of 174 cases where AVTR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
AVTR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.073) is normal, around the industry mean (4.961). P/E Ratio (-20.306) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (0.840) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.614) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AVTR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The RSI Indicator for DXR moved into overbought territory on October 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
DXR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DXR as a result. In 97 of 127 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 76%.
The Moving Average Convergence Divergence Histogram (MACD) for DXR turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 62 similar instances when the indicator turned negative. In 50 of the 62 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
DXR moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DXR crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DXR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
The Aroon Indicator for DXR entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.061) is normal, around the industry mean (4.961). P/E Ratio (5.574) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (3.480) is also within normal values, averaging (4.143). Dividend Yield (0.013) settles around the average of (0.005) among similar stocks. P/S Ratio (8.389) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. DXR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DXR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
AVTR | DXR | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 74 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 73 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 59 | |
PRICE GROWTH RATING 1..100 | 35 | 73 | |
P/E GROWTH RATING 1..100 | 99 | 96 | |
SEASONALITY SCORE 1..100 | n/a | 42 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AVTR's Valuation (33) in the null industry is somewhat better than the same rating for DXR (73) in the Medical Specialties industry. This means that AVTR’s stock grew somewhat faster than DXR’s over the last 12 months.
AVTR's Profit vs Risk Rating (100) in the null industry is in the same range as DXR (100) in the Medical Specialties industry. This means that AVTR’s stock grew similarly to DXR’s over the last 12 months.
DXR's SMR Rating (59) in the Medical Specialties industry is somewhat better than the same rating for AVTR (93) in the null industry. This means that DXR’s stock grew somewhat faster than AVTR’s over the last 12 months.
AVTR's Price Growth Rating (35) in the null industry is somewhat better than the same rating for DXR (73) in the Medical Specialties industry. This means that AVTR’s stock grew somewhat faster than DXR’s over the last 12 months.
DXR's P/E Growth Rating (96) in the Medical Specialties industry is in the same range as AVTR (99) in the null industry. This means that DXR’s stock grew similarly to AVTR’s over the last 12 months.
| AVTR | DXR | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 89% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 75% |
| Momentum ODDS (%) | 1 day ago 68% | 1 day ago 76% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 71% |
| TrendMonth ODDS (%) | 1 day ago 67% | 1 day ago 74% |
| Advances ODDS (%) | 2 days ago 63% | N/A |
| Declines ODDS (%) | 16 days ago 73% | 1 day ago 73% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 84% |
| Aroon ODDS (%) | 1 day ago 63% | 1 day ago 83% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AVTR’s FA Score shows that 0 FA rating(s) are green while DXR’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AVTR’s TA Score shows that 4 TA indicator(s) are bullish while DXR’s TA Score has 2 bullish TA indicator(s).
AVTR (@Pharmaceuticals: Other) experienced а +9.94% price change this week, while DXR (@Pharmaceuticals: Other) price change was -4.33% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
AVTR is expected to report earnings on Oct 28, 2026.
DXR is expected to report earnings on Nov 12, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor indicates that over the last year, AVTR has been loosely correlated with RGEN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AVTR jumps, then RGEN could also see price increases.
| Ticker / NAME | Correlation To AVTR | 1D Price Change % | ||
|---|---|---|---|---|
| AVTR | 100% | -0.64% | ||
| RGEN - AVTR | 46% Loosely correlated | -0.72% | ||
| BCPC - AVTR | 40% Loosely correlated | +1.43% | ||
| AVNT - AVTR | 38% Loosely correlated | -0.27% | ||
| EMBC - AVTR | 36% Loosely correlated | +2.69% | ||
| ICUI - AVTR | 36% Loosely correlated | +4.66% | ||
More | ||||
A.I.dvisor tells us that DXR and IART have been poorly correlated (+33% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DXR and IART's prices will move in lockstep.
| Ticker / NAME | Correlation To DXR | 1D Price Change % | ||
|---|---|---|---|---|
| DXR | 100% | -3.09% | ||
| IART - DXR | 33% Poorly correlated | +4.10% | ||
| BWAY - DXR | 27% Poorly correlated | -4.51% | ||
| AVTR - DXR | 23% Poorly correlated | -0.64% | ||
| COO - DXR | 20% Poorly correlated | +4.54% | ||
| SHC - DXR | 20% Poorly correlated | +2.03% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| DUST | 44.96 | 4.60 | +11.40% |
| Direxion Daily Gold Miners Index Bear 2X ETF (DUST) | |||
| USDX | 25.64 | 0.03 | +0.10% |
| SGI Enhanced Core ETF (USDX) | |||
| HYGM | 23.68 | N/A | N/A |
| Amplify HYG High Yield 10% Target Income ETF (HYGM) | |||
| JELH | 25.70 | -0.04 | -0.16% |
| Janus Henderson Equity Linked High Income ETF (JELH) | |||
| WINN | 33.48 | -0.82 | -2.39% |
| Harbor Long-Term Growers ETF (WINN) | |||